Follistatin: The Most Expensive PED You Will Never Run
I cover follistatin briefly in my YK11 article, to which you may have asked yourself why even bother with YK11's follistatin boosting properties? Just cut out the middleman, and take follistatin, right? As we will see, it's not quite that simple.
Follistatin is a protein expressed in nearly all tissues of humans, and other animals. It is part of the inhibin-activin-follistatin axis that controls cell creation and differentiation. Animals treated with follistatin, which blocks the binding of myostatin to receptors, have significantly larger muscles, with even a 20% reduction in myostatin have an impact on the development of muscle.
In this NPR article that covered monkey trials in 2009, intramuscular injection of follistatin (FS344) shows very specific and localized muscle growth to the muscle it was injected into. NSFW, btw. In human trials, it seems to ‘show promise’, though they’re playing their cards real close to their chest at this point with no real data points available. I’m not sure if this is only effective at the site of injection, but I’m inclined to say it is based on the animal trials. Also, as I said earlier, follistatin exists in nearly all tissues, indicating to me that it has a very local effect – wherever that stuff is concentrated is where the action will occur rather than having an effect on the whole body. Alternatively, YK11 boosts natural follistatin production throughout the entire body - therein lies the difference in action.
Sources on this stuff indicate it is expensive. Few hundred bucks for a milligram, and that’s about what you need over a period of two weeks or so according to the recommended brodose. So this article is more to satiate any curiosity you have on follistatin than a true evaluation of applicability for performance enhancement, unless you’re earning millions of dollars a year, in which case hook a brother up. On the up-side though, if it ever becomes cost effective to run, it seems pretty friendly in terms of side effects. 9 patients who received follistatin therapy have been followed for 4 years, with no adverse events reported.
Conclusion seems pretty obvious, but this is still an area of development worth monitoring. If researchers can figure out a way to boost natural follistatin production, which is under investigation, we will have a very potent and in demand PED. Until that time, just watch this space, and let others spend their time and money on experimenting with this compound.